CurrentCommunity-CarePolicy N/A

Benlysta IV (belimumab) Medical Benefit Medication Utilization Policy

Defines medical benefit coverage criteria, authorization, and coding for intravenous belimumab (Benlysta) for systemic lupus erythematosus and active lupus nephritis for Community-Care members and providers.

Policy Summary

PayerCommunity-Care

PolicyBenlysta IV (belimumab) Medical Benefit Medication Utilization Policy

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateJun 1, 2024

Key ActionObtain prior authorization with documentation of specialty prescriber, diagnosis, supporting serologies, prior therapy failures or intolerance, and patient weight.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

6 monthsinitial authorization period

1 yearcontinuation authorization period

J0490HCPCS code

>=7.5 mgcorticosteroid threshold

Coverage criteria for belimumab (Benlysta)

Initial Therapy - Systemic lupus erythematosus

Covered when ALL of the following are met:

SLE initial criteria

Serology: Documentation of one of: anti-dsDNA positive; low complement C3 or C4; or anti-Smith antibodies
Prior therapies: Two of the following are ineffective, contraindicated, or not tolerated: hydroxychloroquine; methotrexate; azathioprine; mycophenolate mofetil; chronic corticosteroid treatment at >= 7.5 mg prednisone daily or equivalent2 of 5
Exclusions: Does not have severe active CNS lupus; will not be given in combination with other biologics

Policy Summary

PayerCommunity-Care

PolicyBenlysta IV (belimumab) Medical Benefit Medication Utilization Policy

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateJun 1, 2024

Key ActionObtain prior authorization with documentation of specialty prescriber, diagnosis, supporting serologies, prior therapy failures or intolerance, and patient weight.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial Therapy - Active lupus nephritis

Covered when ALL of the following are met:

Lupus nephritis initial criteria: Diagnosis of active lupus nephritis in a patient receiving standard therapy

Prescriber must be or consult with a rheumatologist or nephrologist

Exclusions: Does not have severe active CNS lupus; will not be given in combination with other biologics or with voclosporin

Continuation Therapy

Covered when ALL of the following are met:

Continuation criteria: Prescribed by, or in consultation with, an appropriate specialist; diagnosis of active, autoantibody-positive SLE or active lupus nephritis; documentation of disease stabilization or improvement on belimumab

Must not have severe active CNS lupus; not given with other biologics; if for lupus nephritis, not given with voclosporin

The policy expressly excludes patients with severe active central nervous system (CNS) lupus from coverage for belimumab (Benlysta). Requests for belimumab will also be denied when it is to be administered in combination with other biologic therapies. For the indication of active lupus nephritis, the policy additionally prohibits combination use with voclosporin.

When assessing eligibility, confirm the absence of severe active CNS lupus because its presence is an exclusion for both initial and continuation approvals. Document that belimumab will not be co-administered with any other biologic agent; for patients treated for active lupus nephritis, also document that belimumab will not be used concomitantly with voclosporin. These combination-therapy restrictions apply at both initiation and renewal.

Billing and coding

Applicable HCPCS CodesHCPCSCovered

J0490

Injection, belimumab, 10 mg

Chronic corticosteroid threshold — prednisone-equivalent

Threshold (prednisone-equivalent)>= 7.5 mg prednisone daily (or equivalent)

Context where usedCounts as one of the required two prior therapies for initial SLE approval when chronic corticosteroid treatment meets threshold

Policy locationListed under Initial Approval — Systemic lupus erythematosus, item iv.5

Prior authorization, required documentation, and denial conditions

Prior Authorization

Prior Authorization Required

Prior authorization is required for Benlysta IV. Requests must document the specialty prescriber, diagnosis, supporting serologies, prior therapy history, and intended treatment plan.

Prescriber: rheumatologist, nephrologist, or dermatologist (as appropriate to indication).
Diagnosis: active, autoantibody-positive systemic lupus erythematosus OR active lupus nephritis.
Supporting serologies: anti-dsDNA positive, low complement (C3 or C4), or anti-Smith antibodies.

Step Therapy

Step therapy (Required Prior Therapies)

For systemic lupus erythematosus (SLE) prior to approval, the medical record must show that at least two of the listed standard therapies are ineffective, contraindicated, or not tolerated.

Required trial history must include TWO of the following: hydroxychloroquine; methotrexate; azathioprine; mycophenolate mofetil; chronic corticosteroid therapy ≥ 7.5 mg prednisone daily (or equivalent).
Specify whether each listed therapy was ineffective, not tolerated, or contraindicated and include treatment dates/durations when available.

Documentation Required

Required Documentation

Include the following documentation with the prior authorization request to avoid processing delays.

Specialty prescriber name and specialty (rheumatologist, nephrologist, or dermatologist).
Confirmed diagnosis with indication (active, autoantibody-positive SLE or active lupus nephritis).
Relevant serologies: anti-dsDNA, C3 and C4 complement levels, anti-Smith antibodies.
Detailed prior therapy history: medications tried, dates, reason for discontinuation (ineffective, intolerant, or contraindicated).
Weight (required for dosing and approval).
For continuation requests: documentation of disease stabilization or improvement on belimumab.

Denial Risk

Conditions That Trigger Denial

Requests will be denied when contraindications or exclusion conditions are present.

Severe active central nervous system (CNS) lupus.
Request for concomitant use with other biologic therapies.
For lupus nephritis: concomitant use with voclosporin.
Insufficient documentation of required prior therapies or missing supporting serologies.
Lack of specialty prescriber or missing required weight information.

Background

Belimumab (Benlysta) is an intravenous biologic indicated as adjunctive therapy for active, autoantibody-positive systemic lupus erythematosus and for active lupus nephritis. The policy requires that treatment be prescribed by—or in consultation with—an appropriate specialist (rheumatologist, dermatologist, or nephrologist as applicable) and that serologic evidence of disease activity (for example, anti-dsDNA positivity or low complement C3/C4) or clinical response be documented for initiation and continuation decisions.

Key definitions

Active, autoantibody-positive systemic lupus erythematosus — required laboratory evidence and clinical context

DefinitionSystemic lupus erythematosus with laboratory evidence of autoantibodies in a patient receiving standard therapy

Acceptable serologic evidenceOne of: anti-double stranded DNA (anti-dsDNA) positive; low complement (C3 or C4); or positive anti-Smith antibodies

Prescriber requirementPrescribed by, or in consultation with, a rheumatologist or dermatologist (for SLE)

Exclusion relevant to definitionPatient must not have severe active central nervous system (CNS) lupus